MedTrace Logo

Pharmacokinetics and Safety Between "DWJ1421" and "DWC201903" in Healthy Male Volunteers

NCT04278391 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-02-20

No results posted yet for this study

Summary

This is a randomized, open label, single dose, crossover study to compare the pharmacokinetics and safety between "DWJ1421" and "DWC201903" in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

DWJ1421

1 tablet administered in fasting condition

DRUG

DWC201903

1 tablet administered in fasting condition

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2019-08-10
Completion
2020-02-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278391 on ClinicalTrials.gov